#India #New Delhi #CDMO #EU GMP #Akums Drugs

Akums Expands Presence in Europe and the UK

Akums Drugs & Pharmaceuticals Ltd., reputed as India’s largest Contract Development and Manufacturing Organization (CDMO), has recently made significant strides in its international expansion. This move comes on the heels of acquiring certification under the European Union's Good Manufacturing Practice (EU GMP) for two of its production facilities in India. This development is pivotal as it increases Akums' capability to service regulated global markets while adhering to internationally recognized quality and compliance standards.

Growth in the Pharmaceutical Sector

India has long been dubbed the "pharmacy of the world", contributing approximately 10% to the global pharmaceutical consumption and playing a crucial role in supplying medications to over 1.46 billion people. Akums is at the forefront of this endeavor, solidifying its reputation in the pharma industry. Its recent achievement of EU-GMP certification demonstrates its commitment to maintaining high manufacturing standards and optimizing operational procedures.

The renewal of its facility for solid oral dosage forms—such as tablets and capsules—and the recertification for liquid oral dosage forms, including syrups and solutions, equips Akums to meet the growing demands of regulated markets in Europe and the UK.

Strategic Entry into the UK Market

With an ambitious vision of becoming a leading name in the EU and UK markets, Akums marked its entry into the British market by obtaining its first Medicines and Healthcare products Regulatory Agency (MHRA) approval for the anticoagulant, Rivaroxaban. This strategic maneuver positions Akums directly within the UK anticoagulant sector, a significant segment of the pharmaceutical market valued at approximately $2.6 billion.

Sandeep Jain, Managing Director of Akums, expressed optimism about this milestone, stating, "We have built a reputation for size, compliance, and credibility in India. Now, we intend to replicate this achievement internationally with the same commitment to quality and reliability."

Adding to this sentiment, Co-Managing Director Sanjeev Jain noted, "Our manufacturing strength, regulatory discipline, and development capabilities empower us to confidently enter regulated markets. This represents a meticulously planned yet ambitious global expansion strategy."

An Integrated Ecosystem for Innovation

Akums has successfully established an integrated, innovation-driven front-end ecosystem that spans from the conceptual phase to commercial scale-up. Currently, the company boasts a portfolio exceeding 20,000 Stock Keeping Units (SKUs) and operates four advanced Front-End centers. With expertise in over 60 dosage forms, Akums is proficient in producing complex injectable formulations, solid oral forms, liquids, nutraceuticals, and novel drug delivery systems, thereby offering globally competitive pharmaceutical solutions.

As part of its extensive operational capacity, Akums serves more than 1,500 customers worldwide, managing 14 state-of-the-art manufacturing facilities, which include two Active Pharmaceutical Ingredient (API) plants and twelve formulation plants. Collectively, these facilities possess a remarkable production capacity exceeding 50 billion units annually.

Conclusion

With its increased footprint in Europe and the UK, alongside the nurturing of a wide array of partnerships, Akums Drugs & Pharmaceuticals Ltd. is arguably paving the way for the next phase of global expansion. The firm's strategic initiatives reflect its unwavering commitment to quality, compliance, and reliability as it positions itself as a formidable force in the international pharmaceutical landscape.